ICU Medical, Inc. (ICUI) Stake Lifted by Citigroup Inc.

Citigroup Inc. grew its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 104.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,190 shares of the medical instruments supplier’s stock after purchasing an additional 8,775 shares during the period. Citigroup Inc. owned approximately 0.09% of ICU Medical worth $2,965,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ICUI. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of ICU Medical by 10.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 707 shares of the medical instruments supplier’s stock valued at $122,000 after purchasing an additional 66 shares in the last quarter. Riverhead Capital Management LLC grew its position in shares of ICU Medical by 99.8% during the 2nd quarter. Riverhead Capital Management LLC now owns 999 shares of the medical instruments supplier’s stock valued at $172,000 after purchasing an additional 499 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of ICU Medical by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 1,050 shares of the medical instruments supplier’s stock valued at $181,000 after purchasing an additional 157 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new position in shares of ICU Medical during the 1st quarter valued at $194,000. Finally, Parametrica Management Ltd purchased a new position in shares of ICU Medical during the 2nd quarter valued at $213,000. Hedge funds and other institutional investors own 78.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://ledgergazette.com/2017/09/26/icu-medical-inc-icui-stake-lifted-by-citigroup-inc.html.

ICU Medical, Inc. (ICUI) opened at 181.35 on Tuesday. The company has a 50-day moving average of $173.09 and a 200 day moving average of $164.39. ICU Medical, Inc. has a 12 month low of $124.09 and a 12 month high of $186.25. The stock has a market capitalization of $3.59 billion, a price-to-earnings ratio of 72.63 and a beta of 0.36.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Wednesday, August 9th. The medical instruments supplier reported $0.52 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.58 by ($0.06). The firm had revenue of $331.51 million for the quarter, compared to the consensus estimate of $318.30 million. ICU Medical had a net margin of 6.10% and a return on equity of 7.56%. The firm’s revenue for the quarter was up 242.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.15 earnings per share. On average, equities research analysts anticipate that ICU Medical, Inc. will post $4.11 earnings per share for the current fiscal year.

ICUI has been the subject of a number of recent analyst reports. BidaskClub upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday, June 17th. Sidoti lowered shares of ICU Medical from a “buy” rating to a “neutral” rating in a research report on Tuesday, June 20th. Zacks Investment Research upgraded shares of ICU Medical from a “hold” rating to a “strong-buy” rating and set a $195.00 price target for the company in a research report on Wednesday, July 12th. Finally, Gabelli restated a “buy” rating on shares of ICU Medical in a research report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. ICU Medical has an average rating of “Hold” and a consensus target price of $193.00.

In related news, Director Robert S. Swinney sold 463 shares of the firm’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $181.25, for a total transaction of $83,918.75. Following the completion of the transaction, the director now directly owns 14,330 shares of the company’s stock, valued at $2,597,312.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott E. Lamb sold 23,772 shares of the firm’s stock in a transaction on Tuesday, July 11th. The shares were sold at an average price of $170.02, for a total transaction of $4,041,715.44. Following the transaction, the chief financial officer now directly owns 9,050 shares of the company’s stock, valued at $1,538,681. The disclosure for this sale can be found here. Insiders have sold a total of 213,012 shares of company stock worth $36,438,659 over the last 90 days. Insiders own 15.90% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUI).

Institutional Ownership by Quarter for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply